• Point mutation in DNA-binding domain of HPV-2 E2 studied

Electrophoretic Separations

Point mutation in DNA-binding domain of HPV-2 E2 studied

Feb 15 2012

A point mutation in the DNA-binding domain of HPV-2 E2 protein has been found to increase its DNA-binding capacity and reverses its transcriptional regulatory activity on the viral early promoter.

Researchers have used three forms of analytical research to discover the effects of point mutation in HPV-2 E2 protein. CAT expression assays, Western blots analysis and Electrophoresis mobility shift assays (EMSA) were utilised in the research, that found the mutation from Ala to Val at aa 338 is critical for E2 DNA-binding and its transcriptional regulation.

CAT expression assays were used to find the enhanced promoter activity, indicating that the enhanced promoter activity was due to the co-expressions of the E2 constructs containing A338V mutation within the DNA-binding domain. Western blots analysis then demonstrated that the transiently transfected E2 expressing plasmids were continuously expressed in the cells.

Finally, electrophoresis mobility shift assays (EMSA) showed that the binding affinity of E2 protein with A338V mutation to both an artificial probe with two E2 binding sites or HPV-2 and HPV-16 promoter-proximal LCR sequences were far  stronger than that of the HPV-2 prototype E2.

Posted by Fiona Griffiths

Digital Edition

Chromatography Today - Buyers' Guide 2022

October 2023

In This Edition Modern & Practical Applications - Accelerating ADC Development with Mass Spectrometry - Implementing High-Resolution Ion Mobility into Peptide Mapping Workflows Chromatogr...

View all digital editions


MSB 2024

May 19 2024 Brno, Czech Republic

Water Expo Nigeria 2024

May 21 2024 Lagos, Nigeria

NGVS 2024

May 23 2024 Beijing, China


May 28 2024 Tel Aviv, Israel


May 28 2024 Leuven, Belgium

View all events